ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,127.79
      1.26%
      US Tech 100
      17,446.00
      2.17%
      Dow Jones
      38,675.68
      1.18%
      Brent Oil
      82.765
      0.00%
      Bitcoin
      63,640.66
      1.19%
      Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Genmab AS (GMAB)

      7. Genmab AS (GMAB) News

      GMAB Genmab AS

      29.73
      2.01 (7.25%)
      May 03 2024 - Closed
      Delayed by 15 minutes
      Company Name Stock Ticker Symbol Market Type
      Genmab AS GMAB NASDAQ Depository Receipt
        Price Change Change Percent Stock Price Last Traded
      Upgrade Icon
      2.01 7.25% 29.73 19:05:20
      Open Price Low Price High Price Close Price Prev Close
      29.73 29.46 29.92 29.72 27.72
      more quote information »

      Recent News

      Date Time Source Heading
      4/29/202418:40BWFDA Grants Full Approval for TIVDAK® to Treat Recurrent or..
      4/03/202401:35BWGenmab to Broaden and Strengthen Oncology Portfolio with..
      3/11/202413:43EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      3/04/202413:50EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      3/04/202413:26EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      3/01/202417:04EDGAR2Form 144 - Report of proposed sale of securities
      2/29/202411:47EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      2/28/202411:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      2/27/202416:55EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      2/27/202407:45BWU.S. FDA Accepts for Priority Review the Supplemental..
      2/26/202412:19EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      2/26/202410:40EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      2/22/202416:28EDGAR2Form S-8 - Securities to be offered to employees in employee..
      2/20/202411:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      2/14/202415:42EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      2/14/202413:49EDGAR2Form 20-F - Annual and transition report of foreign private..
      2/14/202412:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      2/02/202406:45BWTisotumab Vedotin Marketing Authorization Application..
      1/31/202411:17EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      1/23/202409:04EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      1/09/202407:45DJNPfizer, Genmab Get Speedy FDA Review of Tivdak Full Approval
      1/09/202406:45BWTIVDAK® (tisotumab vedotin-tftv) Supplemental Biologics..
      1/03/202408:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      12/13/202311:46EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      12/09/202312:00BWNew Pivotal Data for Bispecific Antibody Epcoritamab..
      12/01/202313:15EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      11/27/202307:00BWGenmab Announces Positive Regulatory Updates for Epcoritamab..
      11/21/202316:51EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      11/09/202310:15EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      11/08/202312:24EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      11/07/202311:12EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      11/02/202309:05BWGenmab Announces Multiple Abstracts to be Presented at the..
      10/22/202310:30BWTIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged..
      10/17/202308:22EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      10/05/202310:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      9/28/202316:15EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      9/25/202308:53EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      9/25/202308:50DJNAbbVie, Genmab Get Conditional Europe OK of Tepkinly..
      9/25/202307:45BWGenmab Announces European Commission Approval of TEPKINLY®..
      9/25/202305:55BWEPKINLY™ (epcoritamab) Approved by Japan Ministry of Health,..
      9/13/202309:59EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      9/12/202315:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      9/05/202309:12EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      9/04/202315:00BWSeagen and Genmab Announce TIVDAK® (tisotumab vedotin-tftv)..
      8/16/202313:44EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      8/15/202315:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      8/03/202311:16EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      7/21/202309:08EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      7/21/202304:30BWGenmab Announces AbbVie Receives Positive CHMP Opinion for..
      7/20/202309:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..

      Your Recent History

      NASDAQ
      GMAB
      Genmab AS
      Delayed Upgrade Clock